The future of addiction therapy could soon look a lot like treatment for diabetes.

A California-based addiction treatment company hopes to change the way patients struggling with substance abuse disorder receive a popular form of medication-assisted treatment. If approved, patients could self-administer naltrexone, an opioid antagonist, in the comfort of their own homes — like insulin, but for recovering addicts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why is the Globe featuring articles on its paid homepage that require an additional paid subscription? Insultingly greedy move. Whoever decided that this was a good idea, is clueless.

  • Because off danger of precipitating an acute withdrawal reaction giving naltrexone to an active opiate user this should only be done in a medical setting. But hey, california dope fiends get “kicks” from your grand mal seizure if you want.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy